ADVFN Logo ADVFN
시장 데이터
뉴스
도구
시장
팔로우

Hot Features

피드 팔로우

Follow Feed 커뮤니티에서 거래자 및 투자자와 연결하세요.

실시간 옵션 플로우

포괄적인 옵션 데이터를 탐색하고 옵션 흐름으로 고급 필터를 사용하세요.

모니터

터미널 모니터로 주식 및 자산 관심 목록을 구성하고 모니터링하세요.
로그인 Premium Icon프리미엄 Help Menu
S&P 500
5,180.74
1.03%
US Tech 100
17,599.60
1.04%
다우존스 지수
38,852.27
0.46%
Bitcoin
63,354.43
0.27%
Registration Strip Icon for discussion 같은 생각을 가진 투자자들과 토론할 수 있는 활발한 포럼에서 상호 작용하려면 등록하세요.
등록
  1. 홈
  2. 인베스팅
  3. 주식
  4. 미국
  5. NASDAQ
  6. Nuvalent Inc (NUVL)

  7. Nuvalent Inc (NUVL) 뉴스

NUVL Nuvalent Inc

69.25
-1.10 (-1.56%)
07 5월(5) 2024 - 마감
15분 지연
기업명 주식 심볼 시장 주식 타입
Nuvalent Inc NUVL 나스닥 보통주
  가격 변동 가격 변동 % 주식 가격 최근 거래 시간
Upgrade Icon
-1.10 -1.56% 69.25 08:59:50
개장가 저가 고가 종가 전일 종가
69.99 68.79 70.69 69.25 70.35
시세 정보 더보기 »

최근 뉴스

일자 시간 출처 제목
09/04/202405:30PRNUSNuvalent Presents New Preclinical Data Supporting Profiles..
06/03/202406:52PRNUSNuvalent to Present New Preclinical Data on HER2-Selective..
27/02/202421:00EDGAR2Form S-8 - Securities to be offered to employees in employee..
27/02/202420:42EDGAR2Form 10-K - Annual report [Section 13 and 15(d), not S-K..
27/02/202420:38EDGAR2Form 8-K - Current report
27/02/202420:30PRNUSNuvalent Highlights Pipeline Progress, Reiterates Key..
27/02/202420:15PRNUSNuvalent Receives U.S. FDA Breakthrough Therapy Designation..
12/02/202420:30PRNUSNuvalent Initiates the Phase 2 Portion of ALKOVE-1 Clinical..
01/02/202420:30PRNUSNuvalent to Participate in the Guggenheim Healthcare Talks..
10/01/202406:55EDGAR2Form 4 - Statement of changes in beneficial ownership of..
10/01/202406:54EDGAR2Form 4 - Statement of changes in beneficial ownership of..
10/01/202406:51EDGAR2Form 4 - Statement of changes in beneficial ownership of..
10/01/202406:49EDGAR2Form 4 - Statement of changes in beneficial ownership of..
10/01/202406:46EDGAR2Form 4 - Statement of changes in beneficial ownership of..
10/01/202406:40EDGAR2Form 8-K - Current report
08/01/202420:30PRNUSNuvalent Announces "OnTarget 2026" Operating Plan and Key..
29/12/202307:09EDGAR2Form 4 - Statement of changes in beneficial ownership of..
27/12/202306:31EDGAR2Form 144 - Report of proposed sale of securities
21/12/202320:30PRNUSNuvalent to Present at the 42nd Annual J.P. Morgan..
21/12/202306:56EDGAR2Form 4 - Statement of changes in beneficial ownership of..
21/12/202306:54EDGAR2Form 4 - Statement of changes in beneficial ownership of..
21/12/202306:51EDGAR2Form 4 - Statement of changes in beneficial ownership of..
20/12/202308:00EDGAR2Form 144 - Report of proposed sale of securities
19/12/202307:45EDGAR2Form 144 - Report of proposed sale of securities
19/12/202307:32EDGAR2Form 144 - Report of proposed sale of securities
19/12/202307:23EDGAR2Form 144 - Report of proposed sale of securities
01/12/202306:47EDGAR2Form 4 - Statement of changes in beneficial ownership of..
14/11/202320:50EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
14/11/202320:45EDGAR2Form 8-K - Current report
14/11/202320:30PRNUSNuvalent Highlights Corporate and Pipeline Achievements and..
04/11/202305:43EDGAR2Form 4 - Statement of changes in beneficial ownership of..
01/11/202319:30PRNUSNuvalent to Participate in the BMO Virtual BioPharma..
27/10/202305:47EDGAR2Form 4 - Statement of changes in beneficial ownership of..
25/10/202307:01EDGAR2Form 144 - Report of proposed sale of securities
18/10/202305:07EDGAR2Form 8-K - Current report
18/10/202305:05EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
17/10/202310:55PRNUSNuvalent Announces Pricing of Public Offering of Common..
16/10/202320:39EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
16/10/202320:30PRNUSNuvalent Announces Public Offering of Common Stock
13/10/202319:40EDGAR2Form 8-K - Current report
13/10/202319:30PRNUSNuvalent Reports Preliminary Phase 1 Clinical Data from..
07/10/202305:58EDGAR2Form 4 - Statement of changes in beneficial ownership of..
07/10/202305:56EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/10/202305:24EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/10/202305:12EDGAR2Form 144 - Report of proposed sale of securities
05/10/202305:05EDGAR2Form 8-K - Current report
05/10/202301:21PRNUSPreliminary Phase 1 Dose-Escalation Data from ALKOVE-1 Trial..
20/09/202305:45EDGAR2Form 4 - Statement of changes in beneficial ownership of..
18/09/202319:30PRNUSNuvalent to Present Preliminary Data from ALKOVE-1 Phase 1/2..
07/09/202305:36EDGAR2Form 4 - Statement of changes in beneficial ownership of..

최근 히스토리

NASDAQ
NUVL
Nuvalent
Delayed Upgrade Clock
ADVFN Logo

대한변국
회사 소개
사업
Popular
앱 받기

도움 및 지원받기: kr-support@advfn.com

ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관

© 2024 ADVFN PLC - 모든 권리 보유